Every 8-K that Kiniksa Pharmaceuticals International, plc (KNSA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KNSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KNSA filings page.
Kiniksa Pharmaceuticals International reported second quarter 2026 results highlighted by strong growth in its flagship therapy ARCALYST. ARCALYST net product revenue was $243.6 million in Q2 2026, representing approximately 55% year-over-year growth, and management increased 2026 ARCALYST net product revenue guidance to $980–$995 million. The company noted continued growth in new and repeat prescribers and stated that about 21% of approximately 14,000 multiple-recurrence pericarditis patients were actively on ARCALYST at quarter-end.
Total revenue for Q2 2026 was $243.6 million, generating income from operations of $27.2 million and net income of $25.4 million, or $0.30 diluted EPS. For the first six months of 2026, revenue reached $457.9 million with net income of $48.0 million. Cash, cash equivalents, and short-term investments totaled $525.9 million as of June 30, 2026, with shareholders’ equity of $654.1 million. Kiniksa highlighted clinical progress, including Phase 3 enrollment for KPL-387 in recurrent pericarditis and ongoing preclinical development of KPL-1161, and stated an expectation that its current operating plan will remain cash flow positive on an annual basis.
Kiniksa Pharmaceuticals International, plc held its Annual Meeting of Shareholders on May 29, 2026, where both Class A and higher-vote Class B shares participated. Each Class A share carried one vote, and each Class B share carried ten votes as of the April 6, 2026 record date.
Shareholders re-elected Stephen R. Biggar, G. Bradley Cole and Barry D. Quart as Class II directors to serve until the 2029 Annual Meeting. All director nominees received substantially more votes for than against, with millions of votes in favor and limited opposition or abstentions.
Investors also approved several auditor and compensation items. They confirmed PricewaterhouseCoopers LLP as UK statutory auditors and ratified PwC as US independent registered public accounting firm for the 2026 fiscal year, and authorized the board, through its audit committee, to set PwC’s remuneration.
Shareholders received the UK statutory annual accounts and report for the period ended December 31, 2025 and supported the UK Statutory Directors’ Annual Remuneration Report, the UK Statutory Directors’ Remuneration Policy, and the advisory vote on named executive officer compensation, each passing with strong majorities and relatively low levels of opposition.
Kiniksa Pharmaceuticals International, plc entered into a material definitive agreement with Baker Bros. Advisors LP and affiliated funds. The deed of waiver limits the shareholders’ ability to convert their Class A1 or Class B1 ordinary shares if that conversion would cause them to beneficially own more than 49.9% of Kiniksa’s outstanding voting rights.
The deed can only be amended, waived or terminated with approval from at least 75% of Kiniksa’s outstanding ordinary shares, except when adding additional shareholders to the deed or imposing additional restrictions on the shareholders’ conversion rights.
Kiniksa Pharmaceuticals International, plc reported that Chief Strategy Officer Eben Tessari has decided to resign to pursue another executive role in the life sciences industry. He will leave his officer role on May 15, 2026, but will continue supporting the company as a consultant.
Under a new Consulting Agreement effective May 15, 2026, Tessari will advise on strategic and operational matters and serve as a special advisor to the Science and Research Committee through May 15, 2027, with an option to renew. He will be paid $450 per hour, up to 20 hours per month, plus approved expenses. The company states his resignation is not due to any disagreement regarding its operations, policies, or practices.
Kiniksa Pharmaceuticals International, plc reported strong first quarter 2026 results driven by ARCALYST. Net product revenue reached $214.3 million, representing 56% year-over-year growth, and total revenue was $214.3 million versus $137.8 million a year earlier. Net income rose to $22.6 million, up from $8.5 million, with diluted earnings per share increasing to $0.27 from $0.11.
The company raised its 2026 ARCALYST net sales guidance to a range of $930–$945 million, up from $900–$920 million, citing expanding adoption in recurrent pericarditis. Cash, cash equivalents, and short-term investments increased to $468.1 million as of March 31, 2026. Kiniksa highlighted portfolio progress, including Phase 2 KPL-387 recurrent pericarditis data expected in the second half of 2026 and initiation of a Phase 3 pivotal trial by year-end, as well as ongoing preclinical work on KPL-1161.
Kiniksa Pharmaceuticals International, plc reported a strong turnaround in 2025, moving to profitability on rapid ARCALYST growth. Net product revenue reached $202.1 million in the fourth quarter and $677.6 million for the year, a 62% increase driven by adoption in recurrent pericarditis.
The company generated 2025 net income of $59.0 million, or $0.80 per basic share, compared with a net loss of $43.2 million in 2024. Total 2025 revenue was $677.6 million against operating expenses of $600.3 million, leading to income from operations of $77.2 million.
Kiniksa ended 2025 with $414.1 million in cash, cash equivalents, and short-term investments, up $170.4 million year over year. Management expects ARCALYST 2026 net product revenue of $900–$920 million and highlighted pipeline milestones, including Phase 2 KPL-387 data expected in the second half of 2026 and a planned Phase 1 start for KPL-1161 by the end of 2026.
Kiniksa Pharmaceuticals International, plc reported leadership changes effective January 10, 2026. The board appointed Ross Moat as chief operating officer and principal operating officer. He will keep overseeing commercial operations while taking on broader functional operations under the new title.
The board also appointed Eben Tessari as chief strategy officer, responsible for the company’s strategic, business development and technical operations, as well as its artificial intelligence initiatives. The company stated that there were no changes to the compensation arrangements for either executive in connection with these appointments.
Kiniksa Pharmaceuticals International, plc furnished an update on its 2025 financial performance. The company reported unaudited full-year 2025 ARCALYST net product revenue of $677.5 million. It also disclosed an unaudited gross-to-net figure of 8.4% for the year, indicating the difference between list prices and realized revenue after discounts and allowances. As of December 31, 2025, Kiniksa reported unaudited $414.1 million in cash, cash equivalents and short-term investments and stated that it had no debt. These figures were shared in a press release that is included as an exhibit.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to report that it has released its financial results for the quarter ended September 30, 2025. The company announced these quarterly results in a press release dated October 28, 2025, which is included as Exhibit 99.1. This filing mainly serves to formally furnish that earnings press release to investors and regulators.
Kiniksa Pharmaceuticals International, plc filed a Form 8-K to let investors know it has posted a new investor presentation on its website at investors.kiniksa.com. The company plans to use this presentation, in whole or in part and potentially with modifications, in upcoming meetings with investors, analysts and other audiences.
The investor presentation is furnished as Exhibit 99.1 to this report, with an additional cover page interactive data file listed as Exhibit 104. The filing is informational and does not announce any specific transaction or financial results.